0001104659-24-005579.txt : 20240122 0001104659-24-005579.hdr.sgml : 20240122 20240122161902 ACCESSION NUMBER: 0001104659-24-005579 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240117 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240122 DATE AS OF CHANGE: 20240122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 24549076 BUSINESS ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm243779d1_8k.htm FORM 8-K
false 0001346830 0001346830 2024-01-17 2024-01-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 17, 2024

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
(Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

 

 

 

Item 2.05. Costs Associated with Exit or Disposal Activities.

 

On January 17, 2024, in connection with a review of the company’s strategic priorities, the Board of Directors of Cara Therapeutics, Inc. (the “Company”) approved a strategic reprioritization to focus the Company’s resources on the Company’s late stage clinical program evaluating oral difelikefalin in pruritus associated with notalgia paresthetica, and approved the termination of the Company’s Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease, including the termination of the ongoing KICK 1 and KICK 2 clinical trials. In connection with the termination of the oral chronic kidney disease program, the Board of Directors also approved a reduction in the Company’s workforce, which the Company expects to substantially complete by January 31, 2024. The Company anticipates recognizing between $2.5 million and $3 million in total charges in the first quarter of 2024 in connection with the reduction in force. These charges will consist primarily of one-time cash charges for termination benefits.

 

Item 7.01.Regulation FD Disclosure.

 

On January 22, 2024, the Company issued a press release (the “Press Release”) announcing its strategic reprioritization plan and the reduction in force. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.  

 

Item 8.01.Other Information.

 

After giving effect to the strategic reprioritization and reduction in force described herein, the Company now expects that its capital resources will be sufficient to fund its currently anticipated operating plan into 2026.

 

On January 22, 2024, the Company also announced that Frédérique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.

 

Forward-Looking Statements

 

Statements contained in this report regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s strategic plans to focus its resources on the development of oral difelikefalin for the treatment of pruritus associated with notalgia paresthetica and to discontinue the development of oral difelikefalin in advanced chronic kidney disease, the expected costs of the reduction in force and the timing of recognition of such charges, and the Company’s cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2023. All forward-looking statements contained in this report speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

 

Item 9.01. Financial Statements and Exhibits. 

 

(d) Exhibits

 

Exhibit No.  Description

 

99.1 Press Release dated January 22, 2024
104 Cover page interactive data file (formatted as Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CARA THERAPEUTICS, INC.  
   
By: /s/ RYAN MAYNARD  
  Ryan Maynard  
  Chief Financial Officer  
  (Principal Financial and Accounting Officer)  

 

Date: January 22, 2024

 

3

 

 EX-99.1 2 tm243779d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

 

– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –

 

– Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued –

 

– Planned workforce reduction of up to 50% –

 

– Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 –

 

– Company to host conference call and webcast today at 8:30 a.m. EST –

 

STAMFORD, Conn., January 22, 2024 – Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program.

 

“We are sharpening our clinical focus on the rapidly progressing Phase 2/3 study in NP, which we believe is the therapeutic indication with the greatest commercial potential for oral difelikefalin,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “Following careful consideration, we have decided to discontinue our work in advanced chronic kidney disease (CKD). I would like to thank the patients and investigators who have participated in our advanced CKD clinical program, as well as our employees for their commitment to transforming the lives of CKD patients suffering from pruritus.”

 

Mr. Posner continued, “Unfortunately, as a result of the difficult decision to restructure the Company, many of our talented team members will depart the organization. I am deeply grateful for their dedicated service and support of our mission. We expect the changes we are making to extend our cash runway into 2026, allowing us to reach all expected key value-inflection milestones in the NP clinical program.”

 

Focus on Late-Stage Notalgia Paresthetica Clinical Program

 

Enrollment in the Phase 2/3 clinical program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with NP, known as KOURAGE, is progressing ahead of the Company’s projections. A data readout from the dose-finding portion of the program is expected in the third quarter of 2024. Final topline results from the first pivotal study are expected by the end of 2025 with the second pivotal study results in early 2026.

 

 

 

 

 

 

NP is a common but under-recognized neuropathic disorder characterized by chronic pruritus affecting the upper back. NP is challenging to manage, as there are currently no FDA-approved therapies to treat the disorder. Oral difelikefalin is the only therapy in development for NP. NP represents a sizable, underserved patient population with an estimated addressable market of 650,000 patients in the U.S. who are under the care of a healthcare provider, not accounting for those who are undiagnosed.

 

Leadership Update

 

Frédérique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.

 

“On behalf of the entire Cara team, I would like to express our sincere gratitude to Fred for all her contributions and dedication to the organization over the past 20 years. As one of Cara’s founders, her scientific leadership helped shape the trajectory of the company from start-up to a publicly traded company,” said Mr. Posner.

 

Conference Call & Webcast

 

Cara will host a conference call and webcast today at 8:30 a.m. EST to discuss the corporate update.

 

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

 

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com.

 

About the KOURAGE Phase 2/3 Clinical Program in Notalgia Paresthetica

 

KOURAGE is a Phase 2/3 clinical program evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP). The program is comprised of two studies – KOURAGE 1 and KOURAGE 2 – which are double-blind, placebo-controlled, 8-week studies with patients allowed to roll-over into open-label 52-week extensions.

 

KOURAGE 1 is composed of two parts. The dose-finding portion of KOURAGE 1 (Part A) is expected to include 200 patients who will be randomized equally to four arms (0.25 mg BID, 1.0 mg BID, 2.0 mg BID, placebo BID). The Company expects a data readout from the dose-finding portion of KOURAGE 1 in the third quarter of 2024. This readout will provide key information, specifically the dose and sample size to initiate the Phase 3 portions of the program – Part B of KOURAGE 1 and the second pivotal study KOURAGE 2.

 

 

 

 

 

 

Part B and KOURAGE 2 will be double-blind, placebo-controlled, 8-week studies with patients randomized 1:1 to either difelikefalin or matching placebo. The primary endpoint will be the proportion of patients with a ≥4-point improvement at Week 8 from baseline in the worst itch numeric rating scale. The Company expects final topline results from the first pivotal study by the end of 2025 with the second study by early 2026.

 

About Cara Therapeutics

 

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin, with an ongoing Phase 2/3 clinical program for patients with notalgia paresthetica, a neuropathic disorder characterized by chronic pruritus of the upper back for which there are no FDA-approved therapies. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s strategic plans to focus its resources on the development of oral difelikefalin for the treatment of pruritus associated with notalgia paresthetica and to discontinue the development of oral difelikefalin in advanced chronic kidney disease, the timing of enrollment and data readouts from the Company’s planned and ongoing clinical trials, and the Company’s cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the launch of new products, including that our commercial partners may not perform as expected, risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

 

 

 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 

 EX-101.SCH 3 cara-20240117.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20240117_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20240117_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm243779d1_ex99-1img001.jpg GRAPHIC begin 644 tm243779d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 17, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 17, 2024
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm243779d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2024-01-17 2024-01-17 iso4217:USD shares iso4217:USD shares false 0001346830 8-K 2024-01-17 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cara-20240117.xsd cara-20240117_lab.xml cara-20240117_pre.xml tm243779d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm243779d1_8k.htm": { "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20240117", "dts": { "schema": { "local": [ "cara-20240117.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cara-20240117_lab.xml" ] }, "presentationLink": { "local": [ "cara-20240117_pre.xml" ] }, "inline": { "local": [ "tm243779d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://caratherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243779d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-17", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm243779d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-005579-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-005579-xbrl.zip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end